Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Nora Therapeutics brings in $18mm through Series B round

Executive Summary

Nora Therapeutics Inc. (reproductive medicine) completed an $18mm Series B round led by new investor Novo AS, with returning backers Burrill & Co., Prospect Venture Partners, Rho Ventures, and Vivo Capital also particpating. A Novo partner will join the company’s board. Nora will use the proceeds for continued development of lead candidate NT100, which uses a technology based on granulocyte colony-stimulating factor (G-CSF). NT100 is in Phase II to improve pregnancy success for women who have had recurrent in vitro fertilization (IVF) failures. The company is also planning to conduct a second Phase II trial in patients with inexplicable repeated miscarriages.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies